title: The systemic availability of buprenorphine administered by nasal spray.
abstract: The kinetics and systemic bioavailability of intranasally administered buprenorphine have been investigated in 9 healthy volunteers in an intranasal/intravenous cross-over study. Each subject received a nominal 0.3 mg dose of buprenorphine intranasally followed one week later by a matched dose intravenously. For the intranasal administration mean tmax and mean Cmax were 30.6 min and 1.77 ng mL-1, respectively. Mean intranasal bioavailability was 48.2 +/- 8.35% (mean +/- s.e.m.) of the intravenous value. Intranasal administration may represent a valuable new delivery route for buprenorphine.
authors.affiliation: Pain Clinic, Bispebjerg Hospital, Copenhagen, Denmark.
authors.forename: J
authors.initials: J
authors.lastname: Eriksen
authors.forename: N H
authors.initials: NH
authors.lastname: Jensen
authors.forename: M
authors.initials: M
authors.lastname: Kamp-Jensen
authors.forename: H
authors.initials: H
authors.lastname: Bjarnø
authors.forename: P
authors.initials: P
authors.lastname: Friis
authors.forename: D
authors.initials: D
authors.lastname: Brewster
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D001682:Biological Availability; D002047:Buprenorphine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male
chemical_list: D000336:Aerosols; D002047:Buprenorphine